Emerging research indicates that ipafricept, a experimental agent , could offer a significant advance in managing fibrotic diseases . This compound functions by blocking activin factor- 1B-binding https://junaidnowe663792.activoblog.com/51588535/ipafricept-a-emerging-approach-for-fibrotic-disease